AzTrials
AzTrials

Small Cell Lung Cancer (SCLC)Phase 3NCT07472517

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

A Phase 3 study testing obrixtamig, atezolizumab and carboplatin in people with Small Cell Lung Cancer (SCLC) and Extensive-stage Small Cell Lung Cancer (ES-SCLC), run by Boehringer Ingelheim at 245 sites in 42 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This study is open to adults with advanced small cell lung cancer (SCLC). The purpose of this study is to find out if a study medicine called obrixtamig plus standard treatment (atezolizumab, carboplatin, and etoposide) improves survival when compared to standard treatment alone. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
obrixtamig, atezolizumab and carboplatin
Could I receive a placebo?
No, everyone receives an active treatment
How many people
670 participants
Where
245 sitesin 42 countries
Study dates
13 Apr 2026to 30 Jul 2029
Phase
Phase 3
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients with histologically confirmed Extensive-stage Small Cell Lung Cancer (ES-SCLC)
  • Patients without any previous systemic anti-cancer treatment for ES-SCLC. Patients who received previous systemic anti-cancer treatment during limited stage are eligible if the treatment has been completed more than 6 months before the diagnosis of ES-SCLC.
  • Adequate archival formalin-fixed paraffin-embedded (FFPE) tumour tissue, as specified in the Laboratory Manual, must be available for central laboratory analysis of Delta-like ligand 3 (DLL3) expression status and other biomarkers. The central laboratory investigational VENTANA DLL3 (SP347) RxDx test result must be available prior to randomisation.
  • Patients with asymptomatic brain metastasis are eligible if they meet one of the following criteria:
  • Treatment for brain metastases (e.g. whole brain radiation therapy, stereotactic radiotherapy, or radiosurgery) completed at least 7 days prior to randomisation and the patient is neurologically stable without the use of glucocorticoids or therapeutic anti-convulsant for at least 7 days prior to randomisation
  • Untreated brain metastases that do not require treatment and the patient is neurologically stable without the use of glucocorticoids or therapeutic anti-convulsant for at least 28 days prior to randomisation
Show all 9Show fewer
  • Eastern Cooperative Oncology Group (ECOG) score of 0 or 1
  • Eligible for continuing carboplatin + etoposide + atezolizumab regimen as first-line Standard of care (SoC) treatment within 28 days after the start of the initial cycle of standard therapy
  • Eligible to receive treatment with full dose of atezolizumab, carboplatin, and etoposide as first-line SoC treatment, in accordance with the approved Summary of Product Characteristics if provided centrally or approved local product label if provided by the trial site Further inclusion criteria apply.

Who cannot join

  • Presence of leptomeningeal disease and/or carcinomatous meningitis
  • Previous treatment targeting DLL3 (e.g. T cell engagers (TcEs), cell therapies, antibody-drug conjugates, or radiopharmaceuticals)
  • Radiotherapy of any anatomical site within 7 days prior to randomisation
  • Toxicity from previous treatments that has not resolved to ≤ Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or baseline. Patients with alopecia, any grade, CTCAE ≤Grade 2, asthenia/fatigue, amenorrhea/menstrual disorders any grade, CTCAE Grade ≤2 peripheral neuropathy, and/or CTCAE Grade 2 endocrinopathies controlled by replacement therapy, and toxicities, which are considered irreversible but stable for at least 4 weeks prior to randomisation, per investigator judgment may be eligible. Note: Patients who developed toxicity from the cycle of standard therapy received prior to randomisation are eligible if adequate organ function is ensured as described
  • Patient with active autoimmune disease or a documented history of autoimmune disease that requires systemic treatment (e.g. glucocorticoids or immunosuppressive drugs). Patients with vitiligo, resolved childhood asthma/atopy, alopecia, or any chronic skin condition that does not require systemic therapy, patients with autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone and/or controlled Type 1 diabetes mellitus on a stable insulin regimen may be included if in the opinion of the investigator it is appropriate and safe to do so.
  • Further exclusion criteria apply.

Trial locations and contacts

245 sites in 42 countries. Contact the study team or a site near you to ask about taking part.

Boehringer Ingelheim contact

1-800-243-0127

clintriage.rdg@boehringer-ingelheim.com

245 sites in 42 countries

China33 sites, 33 recruiting

  • Beijing Cancer Hospital

    Beijing, 100036

    Boehringer Ingelheim, 4001200553, china@bitrialsupport.com

    Not yet recruiting

  • Beijing Chest Hospital, Capital Medical University

    Beijing, 101149

    Boehringer Ingelheim, 4001200553, china@bitrialsupport.com

    Recruiting

  • The First Affiliated Hospital Of Bengbu Medical College

    Bengbu, 233004

    Boehringer Ingelheim, 4001200553, china@bitrialsupport.com

    Recruiting

  • Hunan Province Tumor Hospital

    Changsha, 410013

    Boehringer Ingelheim, 4001200553, china@bitrialsupport.com

    Not yet recruiting

  • Sichuan Cancer Hospital

    Chengdu, 610041

    Boehringer Ingelheim, 4001200553, china@bitrialsupport.com

    Recruiting

  • West China Hospital, Sichuan University

    Chengdu, 610041

    Boehringer Ingelheim, 4001200553, china@bitrialsupport.com

    Recruiting

  • Fujian Cancer Hospital

    Fuzhou, 350014

    Boehringer Ingelheim, 4001200553, china@bitrialsupport.com

    Recruiting

  • Sun Yat-Sen University Cancer Center

    Guangzhou, 510060

    Boehringer Ingelheim, 4001200553, china@bitrialsupport.com

    Recruiting

  • The First Affiliated Hospital,Sun Yat-sen University

    Guangzhou, 510080

    Boehringer Ingelheim, 4001200553, china@bitrialsupport.com

    Recruiting

  • The First Affiliated Hospital, Zhejiang University

    Hangzhou, 310003

    Boehringer Ingelheim, 4001200553, china@bitrialsupport.com

    Not yet recruiting

  • Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine

    Hangzhou, 310016

    Boehringer Ingelheim, 4001200553, china@bitrialsupport.com

    Recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, 150081

    Boehringer Ingelheim, 4001200553, china@bitrialsupport.com

    Not yet recruiting

  • Shandong Cancer Hospital

    Jinan, 250117

    Boehringer Ingelheim, 4001200553, china@bitrialsupport.com

    Recruiting

  • Linyi Cancer Hospital

    Linyi, 276034

    Boehringer Ingelheim, 4001200553, china@bitrialsupport.com

    Recruiting

  • The First Affiliated Hospital of Nanchang University

    Nanchang, 330000

    Boehringer Ingelheim, 4001200553, china@bitrialsupport.com

    Recruiting

  • The Second Affiliated Hospital to Nanchang University

    Nanchang, 330006

    Boehringer Ingelheim, 4001200553, china@bitrialsupport.com

    Recruiting

  • Nanjing Drum Tower Hospital

    Nanjing, 210008

    Boehringer Ingelheim, 4001200553, china@bitrialsupport.com

    Recruiting

  • The Affiliated Cancer Hospital, Guangxi Medical University

    Nanning, 530021

    Boehringer Ingelheim, 4001200553, china@bitrialsupport.com

    Recruiting

  • The First Affiliated Hospital of Ningbo University

    Ningbo, 315010

    Boehringer Ingelheim, 4001200553, china@bitrialsupport.com

    Recruiting

  • Shanghai Chest Hospital

    Shanghai, 200030

    Boehringer Ingelheim, 4001200553, china@bitrialsupport.com

    Recruiting

  • Shanghai Pulmonary Hospital

    Shanghai, 200433

    Boehringer Ingelheim, 4001200553, china@bitrialsupport.com

    Recruiting

  • Shanghai Geriatric Medical Center

    Shanghai, 201104

    Boehringer Ingelheim, 4001200553, china@bitrialsupport.com

    Recruiting

  • Shanghai General Hospital

    Shanghai, 210000

    Boehringer Ingelheim, 4001200553, china@bitrialsupport.com

    Recruiting

  • China Shenyang Chest Hospital

    Shenyang, 110000

    Boehringer Ingelheim, 4001200553, china@bitrialsupport.com

    Recruiting

  • Shanxi Cancer hospital

    Taiyuan, 030000

    Boehringer Ingelheim, 4001200553, china@bitrialsupport.com

    Not yet recruiting

  • Tianjin Cancer Hospital

    Tianjin, 300060

    Boehringer Ingelheim, 4001200553, china@bitrialsupport.com

    Recruiting

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, 325000

    Boehringer Ingelheim, 4001200553, china@bitrialsupport.com

    Recruiting

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, 430048

    Boehringer Ingelheim, 4001200553, china@bitrialsupport.com

    Recruiting

  • Xiangyang Central Hospital

    Xiangyang, 441138

    Boehringer Ingelheim, 4001200553, china@bitrialsupport.com

    Recruiting

  • The Affiliated Hospital of Xuzhou Medical College

    Xuzhou, 221006

    Boehringer Ingelheim, 4001200553, china@bitrialsupport.com

    Recruiting

  • Northern Jiangsu People's Hospital

    Yangzhou, 225001

    Boehringer Ingelheim, 4001200553, china@bitrialsupport.com

    Recruiting

  • Henan Cancer Hospital

    Zhengzhou, 450003

    Boehringer Ingelheim, 4001200553, china@bitrialsupport.com

    Not yet recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, 450015

    Boehringer Ingelheim, 4001200553, china@bitrialsupport.com

    Not yet recruiting

Other trials in China

United States17 sites, 17 recruiting

  • Veterans Affairs Ann Arbor Healthcare System

    Ann Arbor, Michigan, 48105

    Boehringer Ingelheim, 833-602-2368, unitedstates@bitrialsupport.com

    Not yet recruiting

  • Emory University

    Atlanta, Georgia, 30322

    Boehringer Ingelheim, 833-602-2368, unitedstates@bitrialsupport.com

    Recruiting

  • University of Maryland School of Medicine

    Baltimore, Maryland, 21201

    Boehringer Ingelheim, 833-602-2368, unitedstates@bitrialsupport.com

    Recruiting

  • Cape Fear Valley Cancer Center

    Fayetteville, North Carolina, 28303

    Boehringer Ingelheim, 833-602-2368, unitedstates@bitrialsupport.com

    Not yet recruiting

  • Bioresearch Partner - Hialeah Hospital

    Hialeah, Florida, 33013

    Boehringer Ingelheim, 833-602-2368, unitedstates@bitrialsupport.com

    Recruiting

  • HCA MidAmerica Division, Inc.

    Kansas City, Missouri, 64132

    Boehringer Ingelheim, 833-602-2368, unitedstates@bitrialsupport.com

    Recruiting

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas, 72205

    Boehringer Ingelheim, 833-602-2368, unitedstates@bitrialsupport.com

    Not yet recruiting

  • Norton Cancer Institute, Downtown

    Louisville, Kentucky, 40202

    Boehringer Ingelheim, 833-602-2368, unitedstates@bitrialsupport.com

    Recruiting

  • University of Wisconsin

    Madison, Wisconsin, 53792

    Boehringer Ingelheim, 833-602-2368, unitedstates@bitrialsupport.com

    Not yet recruiting

  • Baptist Cancer Center - Memphis

    Memphis, Tennessee, 38120

    Boehringer Ingelheim, 833-602-2368, unitedstates@bitrialsupport.com

    Recruiting

  • Infirmary Cancer Care

    Mobile, Alabama, 36607

    Boehringer Ingelheim, 833-602-2368, unitedstates@bitrialsupport.com

    Not yet recruiting

  • Epic Medical Research - Monroe

    Monroe, Louisiana, 71201

    Boehringer Ingelheim, 833-602-2368, unitedstates@bitrialsupport.com

    Recruiting

  • Ochsner Medical Center

    New Orleans, Louisiana, 70121

    Boehringer Ingelheim, 833-602-2368, unitedstates@bitrialsupport.com

    Not yet recruiting

  • University of Nebraska Medical Center

    Omaha, Nebraska, 68198

    Boehringer Ingelheim, 833-602-2368, unitedstates@bitrialsupport.com

    Recruiting

  • Pikeville Medical Center

    Pikeville, Kentucky, 41501

    Boehringer Ingelheim, 833-602-2368, unitedstates@bitrialsupport.com

    Not yet recruiting

  • AHN Cancer Institute - Allegheny General

    Pittsburgh, Pennsylvania, 15212

    Boehringer Ingelheim, 833-602-2368, unitedstates@bitrialsupport.com

    Recruiting

  • Epic Medical Research - Shreveport

    Shreveport, Louisiana, 71105

    Boehringer Ingelheim, 833-602-2368, unitedstates@bitrialsupport.com

    Recruiting

Other trials in United States

Spain17 sites, 17 recruiting

  • Complejo Hospitalario Universitario A Coruña

    A Coruña, 15006

    Boehringer Ingelheim, 900876092, espana@bitrialsupport.com

    Recruiting

  • Hospital del Mar

    Barcelona, 08003

    Boehringer Ingelheim, 900876092, espana@bitrialsupport.com

    Recruiting

  • Hospital Universitari Vall d'Hebron

    Barcelona, 08035

    Boehringer Ingelheim, 900876092, espana@bitrialsupport.com

    Recruiting

  • Institut Català d'Oncologia de Girona.

    Girona, 17007

    Boehringer Ingelheim, 900876092, espana@bitrialsupport.com

    Recruiting

  • Hospital Duran i Reynals

    L'Hospitalet de Llobregat, 08908

    Boehringer Ingelheim, 900876092, espana@bitrialsupport.com

    Recruiting

  • H. Universitario Insular de Canarias

    Las Palmas de Gran Canaria, 35016

    Boehringer Ingelheim, 900876092, espana@bitrialsupport.com

    Recruiting

  • Hospital Universitario Ramon Y Cajal

    Madrid, 28034

    Boehringer Ingelheim, 900876092, espana@bitrialsupport.com

    Recruiting

  • Fundación Jiménez Díaz

    Madrid, 28040

    Boehringer Ingelheim, 900876092, espana@bitrialsupport.com

    Recruiting

  • Hospital Universitario 12 de Octubre

    Madrid, 28041

    Boehringer Ingelheim, 900876092, espana@bitrialsupport.com

    Recruiting

  • Hospital Puerta de Hierro

    Madrid, 28222

    Boehringer Ingelheim, 900876092, espana@bitrialsupport.com

    Recruiting

  • Hospital Regional Universitario de Malaga

    Málaga, 29010

    Boehringer Ingelheim, 900876092, espana@bitrialsupport.com

    Recruiting

  • Hospital Son Espases

    Palma de Mallorca, 07120

    Boehringer Ingelheim, 900876092, espana@bitrialsupport.com

    Recruiting

  • Clínica Universidad de Navarra

    Pamplona, 31008

    Boehringer Ingelheim, 900876092, espana@bitrialsupport.com

    Recruiting

  • Hospital Universitario Virgen De La Macarena

    Seville, 41009

    Boehringer Ingelheim, 900876092, espana@bitrialsupport.com

    Recruiting

  • Hospital Clinico Universitario de Valencia

    Valencia, 46010

    Boehringer Ingelheim, 900876092, espana@bitrialsupport.com

    Recruiting

  • Hospital Universitari i Politècnic La Fe

    Valencia, 46016

    Boehringer Ingelheim, 900876092, espana@bitrialsupport.com

    Recruiting

  • Hospital Clinico Universitario Lozano Blesa

    Zaragoza, 50009

    Boehringer Ingelheim, 900876092, espana@bitrialsupport.com

    Recruiting

Other trials in Spain

Germany15 sites, 15 recruiting

  • Universitätsklinikum Aachen, AöR

    Aachen, 52074

    Boehringer Ingelheim, 08007234742, deutschland@bitrialsupport.com

    Recruiting

  • Charité - Universitätsmedizin Berlin

    Berlin, 13353

    Boehringer Ingelheim, 08007234742, deutschland@bitrialsupport.com

    Not yet recruiting

  • Vivantes Klinikum Spandau

    Berlin-Spandau, 13585

    Boehringer Ingelheim, 08007234742, deutschland@bitrialsupport.com

    Recruiting

  • Technische Universität Dresden

    Dresden, 01307

    Boehringer Ingelheim, 08007234742, deutschland@bitrialsupport.com

    Not yet recruiting

  • Universitätsklinikum Essen AöR

    Essen, 45147

    Boehringer Ingelheim, 08007234742, deutschland@bitrialsupport.com

    Not yet recruiting

  • Universitätsklinikum Frankfurt

    Frankfurt, 60590

    Boehringer Ingelheim, 08007234742, deutschland@bitrialsupport.com

    Recruiting

  • Universitätsklinikum Freiburg

    Freiburg im Breisgau, 79106

    Boehringer Ingelheim, 08007234742, deutschland@bitrialsupport.com

    Not yet recruiting

  • Asklepios Fachkliniken München-Gauting

    Gauting, 82131

    Boehringer Ingelheim, 08007234742, deutschland@bitrialsupport.com

    Recruiting

  • Universitätsmedizin Göttingen, Georg-August-Universität

    Göttingen, 37075

    Boehringer Ingelheim, 08007234742, deutschland@bitrialsupport.com

    Not yet recruiting

  • LungenClinic Grosshansdorf GmbH

    Großhansdorf, 22927

    Boehringer Ingelheim, 08007234742, deutschland@bitrialsupport.com

    Not yet recruiting

  • Asklepios Kliniken GmbH & Co. KGaA

    Hamburg, 21075

    Boehringer Ingelheim, 08007234742, deutschland@bitrialsupport.com

    Recruiting

  • Thoraxklinik-Heidelberg gGmbH am Universitätsklinikum Heidelberg

    Heidelberg, 69126

    Boehringer Ingelheim, 08007234742, deutschland@bitrialsupport.com

    Recruiting

  • Westfälische Wilhelms-Universität Münster

    Münster, 48149

    Boehringer Ingelheim, 08007234742, deutschland@bitrialsupport.com

    Not yet recruiting

  • Pius-Hospital, Oldenburg

    Oldenburg, 26121

    Boehringer Ingelheim, 08007234742, deutschland@bitrialsupport.com

    Recruiting

  • Universitätsklinikum Würzburg AÖR

    Würzburg, 97078

    Boehringer Ingelheim, 08007234742, deutschland@bitrialsupport.com

    Recruiting

Other trials in Germany

Japan12 sites, 12 recruiting

  • Fujita Health University Hospital

    Aichi, Toyoake, 470-1192

    Boehringer Ingelheim, 05050508862, nippon@bitrialsupport.com

    Recruiting

  • Hirosaki University Hospital

    Aomori, Hirosaki, 036-8563

    Boehringer Ingelheim, 05050508862, nippon@bitrialsupport.com

    Recruiting

  • Kyushu University Hospital

    Fukuoka, Fukuoka, 812-8582

    Boehringer Ingelheim, 05050508862, nippon@bitrialsupport.com

    Recruiting

  • Hokkaido University Hospital

    Hokkaido, Sapporo, 060-8648

    Boehringer Ingelheim, 05050508862, nippon@bitrialsupport.com

    Recruiting

  • Kagoshima University Hospital

    Kagoshima, Kagoshima, 890-8520

    Boehringer Ingelheim, 05050508862, nippon@bitrialsupport.com

    Recruiting

  • Sendai Kousei Hospital

    Miyagi, Sendai, 981-0914

    Boehringer Ingelheim, 05050508862, nippon@bitrialsupport.com

    Recruiting

  • Kindai University Hospital

    Osaka, Sakai, 590-0197

    Boehringer Ingelheim, 05050508862, nippon@bitrialsupport.com

    Recruiting

  • Saitama Medical University International Medical Center

    Saitama, Hidaka, 350-1298

    Boehringer Ingelheim, 05050508862, nippon@bitrialsupport.com

    Recruiting

  • Hamamatsu University Hospital

    Shizuoka, Hamamatsu, 431-3192

    Boehringer Ingelheim, 05050508862, nippon@bitrialsupport.com

    Recruiting

  • National Cancer Center Hospital

    Tokyo, Chuo-ku, 104-0045

    Boehringer Ingelheim, 05050508862, nippon@bitrialsupport.com

    Not yet recruiting

  • Japanese Foundation for Cancer Research

    Tokyo, Koto-ku, 135-8550

    Boehringer Ingelheim, 05050508862, nippon@bitrialsupport.com

    Recruiting

  • Wakayama Medical University Hospital

    Wakayama, Wakayama, 641-8510

    Boehringer Ingelheim, 05050508862, nippon@bitrialsupport.com

    Recruiting

Other trials in Japan

France10 sites, 10 recruiting

  • INS Cancérologie de l'Ouest

    Angers, 49055

    Boehringer Ingelheim, 0805102354, france@bitrialsupport.com

    Not yet recruiting

  • INS Bergonie

    Bordeaux, 33000

    Boehringer Ingelheim, 0805102354, france@bitrialsupport.com

    Recruiting

  • CTR François Baclesse

    Caen, 14076

    Boehringer Ingelheim, 0805102354, france@bitrialsupport.com

    Recruiting

  • CTR Georges-François Leclerc

    Dijon, 21079

    Boehringer Ingelheim, 0805102354, france@bitrialsupport.com

    Not yet recruiting

  • HOP Nord Laennec

    Nantes, 44093

    Boehringer Ingelheim, 0805102354, france@bitrialsupport.com

    Recruiting

  • INS Curie

    Paris, 75005

    Boehringer Ingelheim, 0805102354, france@bitrialsupport.com

    Recruiting

  • Hôpital Cochin

    Paris, 75014

    Boehringer Ingelheim, 0805102354, france@bitrialsupport.com

    Recruiting

  • Hôpital Larrey - CHU de Toulouse

    Toulouse, 31059

    Boehringer Ingelheim, 0805102354, france@bitrialsupport.com

    Not yet recruiting

  • HOP Villefranche-sur-Saône

    Villefranche-sur-Saône, 69400

    Boehringer Ingelheim, 0805102354, france@bitrialsupport.com

    Recruiting

  • Institut Gustave Roussy

    Villejuif, 94800

    Boehringer Ingelheim, 0805102354, france@bitrialsupport.com

    Not yet recruiting

Other trials in France

Italy10 sites, 10 recruiting

  • Centro di riferimento Oncologico

    Aviano (PN), 33081

    Boehringer Ingelheim, 800977373, italia@bitrialsupport.com

    Not yet recruiting

  • Istituto Tumori Giovanni Paolo II

    Bari, 70124

    Boehringer Ingelheim, 800977373, italia@bitrialsupport.com

    Not yet recruiting

  • ASST degli Spedali Civili di Brescia

    Brescia, 25123

    Boehringer Ingelheim, 800977373, italia@bitrialsupport.com

    Not yet recruiting

  • A. O. Universitaria Careggi

    Florence, 50134

    Boehringer Ingelheim, 800977373, italia@bitrialsupport.com

    Not yet recruiting

  • Istituto Scientifico Romagnolo

    Meldola (FC), 47014

    Boehringer Ingelheim, 800977373, italia@bitrialsupport.com

    Recruiting

  • AOU San Luigi Gonzaga

    Orbassano (TO), 10043

    Boehringer Ingelheim, 800977373, italia@bitrialsupport.com

    Not yet recruiting

  • Istituto Oncologico Veneto IRCCS

    Padova, 35128

    Boehringer Ingelheim, 800977373, italia@bitrialsupport.com

    Not yet recruiting

  • Azienda Ospedaliera Unversitaria di Parma

    Parma, 43100

    Boehringer Ingelheim, 800977373, italia@bitrialsupport.com

    Not yet recruiting

  • Fondazione Policlinico Universitario Campus Bio-medico

    Roma, 00128

    Boehringer Ingelheim, 800977373, italia@bitrialsupport.com

    Recruiting

  • Azienda Ospedaliera Universitaria Integrata Verona

    Verona, 37126

    Boehringer Ingelheim, 800977373, italia@bitrialsupport.com

    Recruiting

Other trials in Italy

South Korea10 sites, 10 recruiting

  • Pusan National University Hospital

    Busan, 49241

    Boehringer Ingelheim, 0808802084, namhan@bitrialsupport.com

    Recruiting

  • Chungnam National University Hospital

    Daejoen, 35015

    Boehringer Ingelheim, 0808802084, namhan@bitrialsupport.com

    Recruiting

  • National Cancer Center

    Goyang, 10408

    Boehringer Ingelheim, 0808802084, namhan@bitrialsupport.com

    Recruiting

  • Chonnam National University Hwasun Hospital

    Hwasun, 58128

    Boehringer Ingelheim, 0808802084, namhan@bitrialsupport.com

    Recruiting

  • Seoul National University Bundang Hospital

    Seongnam, 13620

    Boehringer Ingelheim, 0808802084, namhan@bitrialsupport.com

    Recruiting

  • Seoul National University Hospital

    Seoul, 03080

    Boehringer Ingelheim, 0808802084, namhan@bitrialsupport.com

    Recruiting

  • Severance Hospital

    Seoul, 03722

    Boehringer Ingelheim, 0808802084, namhan@bitrialsupport.com

    Recruiting

  • Asan Medical Center

    Seoul, 05505

    Boehringer Ingelheim, 0808802084, namhan@bitrialsupport.com

    Recruiting

  • Samsung Medical Center

    Seoul, 06351

    Boehringer Ingelheim, 0808802084, namhan@bitrialsupport.com

    Recruiting

  • Korea University Guro Hospital

    Seoul, 08308

    Boehringer Ingelheim, 0808802084, namhan@bitrialsupport.com

    Recruiting

Other trials in South Korea

Turkey (Türkiye)10 sites, 10 recruiting

  • Adana Şehir Hastanesi

    Adana

    Boehringer Ingelheim, 08006212470, turkiye@bitrialsupport.com

    Not yet recruiting

  • Medical Park Adana Hastanesi

    Adana

    Boehringer Ingelheim, 08006212470, turkiye@bitrialsupport.com

    Not yet recruiting

  • Sağlık Bilimleri Üniversitesi Gülhane Eğitim ve Araştırma Hastanesi

    Ankara, 06018

    Boehringer Ingelheim, 08006212470, turkiye@bitrialsupport.com

    Not yet recruiting

  • Ankara Liv Hastanesi

    Ankara

    Boehringer Ingelheim, 08006212470, turkiye@bitrialsupport.com

    Not yet recruiting

  • Dr. Abdurrahman Yurtaslan Ankara Onkoloji Eğitim ve Araştırma Hastanesi

    Ankara

    Boehringer Ingelheim, 08006212470, turkiye@bitrialsupport.com

    Not yet recruiting

  • Samsun Medical Park Hastanesi

    Atakum

    Boehringer Ingelheim, 08006212470, turkiye@bitrialsupport.com

    Not yet recruiting

  • Medeniyet University

    Istanbul, 34862

    Boehringer Ingelheim, 08006212470, turkiye@bitrialsupport.com

    Not yet recruiting

  • Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi

    Istanbul, 34890

    Boehringer Ingelheim, 08006212470, turkiye@bitrialsupport.com

    Not yet recruiting

  • Ege Üniversitesi Tıp Fakültesi

    Izmir

    Boehringer Ingelheim, 08006212470, turkiye@bitrialsupport.com

    Not yet recruiting

  • Ankara Bilkent Sehir Hastanesi

    Türkiye

    Boehringer Ingelheim, 08006212470, turkiye@bitrialsupport.com

    Not yet recruiting

Other trials in Turkey (Türkiye)

Mexico7 sites, 7 recruiting

  • Centro Medico Nacional de Occidente/ Centro De Investigacion Biomedica De Occidente

    Guadalajara, Jalisco, 44329

    Boehringer Ingelheim, 018000623749, mexico@bitrialsupport.com

    Not yet recruiting

  • Centro Oncologico Personalizado

    México, 06760

    Boehringer Ingelheim, 018000623749, mexico@bitrialsupport.com

    Not yet recruiting

  • Instituto Nacional de Cancerologia

    México, 14080

    Boehringer Ingelheim, 018000623749, mexico@bitrialsupport.com

    Not yet recruiting

  • Health Pharma Professional Research S.A. de C.V.

    Mexico City, 03100

    Boehringer Ingelheim, 018000623749, mexico@bitrialsupport.com

    Not yet recruiting

  • Centro Medico Zambrano Hellion

    Monterrey, 66278

    Boehringer Ingelheim, 018000623749, mexico@bitrialsupport.com

    Not yet recruiting

  • Hospital Universitario Dr Jose Eleuterio Gonzalez

    Nuevo León, 64460

    Boehringer Ingelheim, 018000623749, mexico@bitrialsupport.com

    Not yet recruiting

  • Centro Oncologico Estatal ISSEMyM "Dr. Jose Luis Barrera Franco"

    Toluca, 50180

    Boehringer Ingelheim, 018000623749, mexico@bitrialsupport.com

    Not yet recruiting

Other trials in Mexico

Taiwan7 sites, 7 recruiting

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    Kaohsiung City, 807

    Boehringer Ingelheim, 0809092098, taiwan@bitrialsupport.com

    Recruiting

  • Taichung Veterans General Hospital

    Taichung, 40705

    Boehringer Ingelheim, 0809092098, taiwan@bitrialsupport.com

    Recruiting

  • National Cheng Kung University Hospital

    Tainan, 70403

    Boehringer Ingelheim, 0809092098, taiwan@bitrialsupport.com

    Recruiting

  • National Taiwan University Hospital

    Taipei, 10048

    Boehringer Ingelheim, 0809092098, taiwan@bitrialsupport.com

    Recruiting

  • National Taiwan University Cancer Center

    Taipei, 106

    Boehringer Ingelheim, 0809092098, taiwan@bitrialsupport.com

    Not yet recruiting

  • Taipei Veterans General Hospital

    Taipei, 11217

    Boehringer Ingelheim, 0809092098, taiwan@bitrialsupport.com

    Recruiting

  • Chang Gung Memorial Hospital, Linkou

    Taoyuan City, 333

    Boehringer Ingelheim, 0809092098, taiwan@bitrialsupport.com

    Recruiting

Other trials in Taiwan

Hungary6 sites, 6 recruiting

  • Koranyi National Institute For Pulmonolgy

    Budapest, 1121

    Boehringer Ingelheim, 680017725, magyarorszag@bitrialsupport.com

    Not yet recruiting

  • University of Debrecen Clinical Centre

    Debrecen, 4032

    Boehringer Ingelheim, 680017725, magyarorszag@bitrialsupport.com

    Not yet recruiting

  • Bekes County Central Hospital

    Gyula, 5700

    Not yet recruiting

  • Bacs-Kiskun Megyei Onkormanyzat Hospital

    Kecskemét, 6000

    Boehringer Ingelheim, 680017725, magyarorszag@bitrialsupport.com

    Not yet recruiting

  • Tolna County Balassa Janos Hospital

    Szekszárd, 7100

    Boehringer Ingelheim, 680017725, magyarorszag@bitrialsupport.com

    Not yet recruiting

  • Reformed Pulmonology Center

    Törökbálint, 2045

    Boehringer Ingelheim, 680017725, magyarorszag@bitrialsupport.com

    Not yet recruiting

Other trials in Hungary

Argentina5 sites, 5 recruiting

  • Hospital Britanico de Buenos Aires

    CABA, 1280AEB

    Boehringer Ingelheim, 08002667801, argentina@bitrialsupport.com

    Recruiting

  • Clinica Adventista Belgrano

    CABA, 1430

    Boehringer Ingelheim, 08002667801, argentina@bitrialsupport.com

    Recruiting

  • Clinica Privada Independencia

    Munro, B1605

    Boehringer Ingelheim, 08002667801, argentina@bitrialsupport.com

    Recruiting

  • Sanatorio Allende S.A.

    Nueva Córdoba, X5000JHQ

    Boehringer Ingelheim, 08002667801, argentina@bitrialsupport.com

    Recruiting

  • Sanatorio Parque S.A.

    Rosario, S2000DSV

    Boehringer Ingelheim, 08002667801, argentina@bitrialsupport.com

    Recruiting

Other trials in Argentina

Chile5 sites, 5 recruiting

  • Icegclinic

    La Florida, 8240000

    Boehringer Ingelheim, 800392345, chile@bitrialsupport.com

    Recruiting

  • Clinica Santa Maria

    Providencia

    Boehringer Ingelheim, 800392345, chile@bitrialsupport.com

    Recruiting

  • Instituto Oncologico FALP

    Providencia

    Boehringer Ingelheim, 800392345, chile@bitrialsupport.com

    Not yet recruiting

  • Bradford Hill- Centro de Investigacion Clinica

    Recoleta, 8420383

    Boehringer Ingelheim, 800392345, chile@bitrialsupport.com

    Not yet recruiting

  • Clinica Alemana de Santiago S.A.

    Santiago, 7650568

    Boehringer Ingelheim, 800392345, chile@bitrialsupport.com

    Not yet recruiting

Other trials in Chile

Malaysia5 sites, 5 recruiting

  • Hospital Pulau Pinang-Georgetown, Pulau Pinang-40766

    George Town, 10450

    Boehringer Ingelheim, 1800814353, malaysia@bitrialsupport.com

    Recruiting

  • Hospital Wanita Dan Kanak-Kanak Sabah

    Kota Kinabalu, 88996

    Boehringer Ingelheim, 1800814353, malaysia@bitrialsupport.com

    Recruiting

  • Sarawak General Hospital

    Kuching, 93586

    Boehringer Ingelheim, 1800814353, malaysia@bitrialsupport.com

    Recruiting

  • National Cancer Institute (IKN)

    Putrajaya, 62250

    Boehringer Ingelheim, 1800814353, malaysia@bitrialsupport.com

    Recruiting

  • Sunway Medical Centre

    Selangor Darul Ehsan, 47500

    Boehringer Ingelheim, 1800814353, malaysia@bitrialsupport.com

    Recruiting

Other trials in Malaysia

Portugal5 sites, 5 recruiting

  • ULS de Braga, E.P.E

    Braga, 4710-243

    Boehringer Ingelheim, 800856070, portugal@bitrialsupport.com

    Recruiting

  • CHUC - Centro Hospitalar e Universitario de Coimbra, EPE

    Coimbra, 3004-561

    Boehringer Ingelheim, 800856070, portugal@bitrialsupport.com

    Not yet recruiting

  • Hospital da Luz

    Lisbon, 1500-650

    Boehringer Ingelheim, 800856070, portugal@bitrialsupport.com

    Recruiting

  • Hospital CUF Porto

    Porto, 4100-180

    Boehringer Ingelheim, 800856070, portugal@bitrialsupport.com

    Recruiting

  • IPO Porto Francisco Gentil, EPE

    Porto, 4200-072

    Boehringer Ingelheim, 800856070, portugal@bitrialsupport.com

    Not yet recruiting

Other trials in Portugal

United Kingdom5 sites, 5 recruiting

  • Velindre Cancer Centre

    Cardiff, CF14 2TL

    Boehringer Ingelheim, 08000514022, unitedkingdom@bitrialsupport.com

    Not yet recruiting

  • Leicester Royal Infirmary

    Leicester, LE1 5WW

    Boehringer Ingelheim, 08000514022, unitedkingdom@bitrialsupport.com

    Recruiting

  • The Christie

    Manchester, M20 4BX

    Boehringer Ingelheim, 08000514022, unitedkingdom@bitrialsupport.com

    Recruiting

  • The Royal Marsden Hospital, Sutton

    Sutton, SM2 5PT

    Boehringer Ingelheim, 08000514022, unitedkingdom@bitrialsupport.com

    Recruiting

  • Torbay Hospital

    Torquay, TQ2 7AA

    Boehringer Ingelheim, 08000514022, unitedkingdom@bitrialsupport.com

    Recruiting

Other trials in United Kingdom

Belgium4 sites, 4 recruiting

  • Centre Hospitalier Interrégional Edith Cavell (CHIREC)

    Brussels, 1160

    Boehringer Ingelheim, 080049616, belgique@bitrialsupport.com

    Not yet recruiting

  • Universitair Ziekenhuis Antwerpen

    Edegem, 2650

    Boehringer Ingelheim, 080049616, belgique@bitrialsupport.com

    Not yet recruiting

  • Universitair Ziekenhuis Brussel

    Jette, 1090

    Boehringer Ingelheim, 080049616, belgique@bitrialsupport.com

    Not yet recruiting

  • UZ Leuven

    Leuven, 3000

    Boehringer Ingelheim, 080049616, belgique@bitrialsupport.com

    Not yet recruiting

Other trials in Belgium

Brazil4 sites, 4 recruiting

  • Hospital de Amor

    Barretos, 14784-400

    Boehringer Ingelheim, 08008919295, brasil@bitrialsupport.com

    Recruiting

  • Centro Gaucho Integrado de Oncologia, Hematologia, Ensino e Pesquisa Sociedade Simples

    Porto Alegre, 90110-270

    Boehringer Ingelheim, 08008919295, brasil@bitrialsupport.com

    Recruiting

  • Irmandade da Santa Casa de Misericórdia de Porto Alegre

    Porto Alegre - RS, CEP 90020-090

    Boehringer Ingelheim, 08008919295, brasil@bitrialsupport.com

    Recruiting

  • Fundaçao Faculdade Regional de Medicina de Sao Jose do Rio Preto

    São José do Rio Preto, 15090-000

    Boehringer Ingelheim, 08008919295, brasil@bitrialsupport.com

    Recruiting

Other trials in Brazil

Poland4 sites, 4 recruiting

  • UCK Clinical Research Support Center

    Gdansk, 80-214

    Boehringer Ingelheim, 008001218830, polska@bitrialsupport.com

    Not yet recruiting

  • Polish Mother's Memorial Hospital - Research Institute

    Lodz, 93338

    Boehringer Ingelheim, 008001218830, polska@bitrialsupport.com

    Recruiting

  • University Clinical Hospital No. 4 in Lublin

    Lublin, 20090

    Boehringer Ingelheim, 008001218830, polska@bitrialsupport.com

    Not yet recruiting

  • Warmia and Mazury Center for Lung Diseases in Olsztyn

    Olsztyn, 10-357

    Boehringer Ingelheim, 008001218830, polska@bitrialsupport.com

    Not yet recruiting

Other trials in Poland

Thailand4 sites, 4 recruiting

  • Vajira Hospital

    Bangkok, 10300

    Boehringer Ingelheim, 1800019059, thai@bitrialsupport.com

    Recruiting

  • Siriraj Hospital

    Bangkok, 10700

    Boehringer Ingelheim, 1800019059, thai@bitrialsupport.com

    Recruiting

  • Maharaj Nakom Chiangmai Hospital

    Chiang Mai, 50200

    Boehringer Ingelheim, 1800019059, thai@bitrialsupport.com

    Recruiting

  • Songklanagarind Hospital

    Hat Yai, 90110

    Boehringer Ingelheim, 1800019059, thai@bitrialsupport.com

    Recruiting

Other trials in Thailand

Vietnam4 sites, 4 recruiting

  • Hanoi Oncology Hospital

    Hanoi, 100000

    Boehringer Ingelheim, 01800545473, vietnam@bitrialsupport.com

    Not yet recruiting

  • Vietnam National Cancer Hospital

    Hanoi, 100000

    Boehringer Ingelheim, 01800545473, vietnam@bitrialsupport.com

    Not yet recruiting

  • Ho Chi Minh Oncology Hospital

    Ho Chi Minh City, 70000

    Boehringer Ingelheim, 01800545473, vietnam@bitrialsupport.com

    Not yet recruiting

  • University Medical Center HCMC

    Ho Chi Minh City, 70000

    Boehringer Ingelheim, 01800545473, vietnam@bitrialsupport.com

    Not yet recruiting

Other trials in Vietnam

Australia3 sites, 3 recruiting

  • Cancer Research South Australia

    Adelaide, South Australia, 5000

    Boehringer Ingelheim, 1800271035, australia@bitrialsupport.com

    Recruiting

  • Ballarat Regional Integrated Cancer Centre

    Ballarat, Victoria, 3350

    Boehringer Ingelheim, 1800271035, australia@bitrialsupport.com

    Recruiting

  • Prince of Wales Hospital-Randwick-66496

    Randwick, New South Wales, 2031

    Boehringer Ingelheim, 1800271035, australia@bitrialsupport.com

    Recruiting

Other trials in Australia

Austria3 sites, 3 recruiting

  • Hospital Elisabethinen Linz

    Linz, 4020

    Boehringer Ingelheim, 0800017900, oesterreich@bitrialsupport.com

    Recruiting

  • Johannes Kepler University Linz

    Linz, 4020

    Boehringer Ingelheim, 0800017900, oesterreich@bitrialsupport.com

    Not yet recruiting

  • Standort Penzing der Klinik Ottakring

    Vienna, 1160

    Boehringer Ingelheim, 0800017900, oesterreich@bitrialsupport.com

    Not yet recruiting

Other trials in Austria

Bulgaria3 sites, 3 recruiting

  • Multiprofile Hospital For Active Treatment-Uni Hospital Ltd.

    Panagyurishte, 4500

    Boehringer Ingelheim, 024903378, balgariya@bitrialsupport.com

    Not yet recruiting

  • MHAT Heart and brain

    Pleven, 5800

    Boehringer Ingelheim, 024903378, balgariya@bitrialsupport.com

    Not yet recruiting

  • Acibadem City Clinic Tokuda University Hospital EAD

    Sofia, 1407

    Boehringer Ingelheim, 024903378, balgariya@bitrialsupport.com

    Not yet recruiting

Other trials in Bulgaria

Finland3 sites, 3 recruiting

  • KYS Sädesairaala

    Kuopio, 70029

    Boehringer Ingelheim, 0800918118, suomi@bitrialsupport.com

    Recruiting

  • Oulun yliopistollinen keskussairaala

    Oulu, 90220

    Boehringer Ingelheim, 0800918118, suomi@bitrialsupport.com

    Recruiting

  • Turun Yliopistollinen sairaala

    Turku, 20521

    Boehringer Ingelheim, 0800918118, suomi@bitrialsupport.com

    Not yet recruiting

Other trials in Finland

Greece3 sites, 3 recruiting

  • Chest Hospital of Athens "Sotiria"

    Athens, 115 27

    Boehringer Ingelheim, 008000000092, hellas@bitrialsupport.com

    Not yet recruiting

  • Henry Dunant Hospital, Athens

    Athens, 11526

    Boehringer Ingelheim, 008000000092, hellas@bitrialsupport.com

    Recruiting

  • General Hospital of Thessaloniki "G. Papanikolaou"

    Thessaloniki, 57010

    Boehringer Ingelheim, 008000000092, hellas@bitrialsupport.com

    Recruiting

Other trials in Greece

Netherlands3 sites, 3 recruiting

  • Nederlands Kanker Instituut - Antoni van Leeuwenhoek Amsterdam (METC AVL)

    Amsterdam, 1066CX

    Boehringer Ingelheim, 08000204613, nederland@bitrialsupport.com

    Recruiting

  • Maastricht University Medisch Centrum

    Maastricht, 6229 HX

    Boehringer Ingelheim, 08000204613, nederland@bitrialsupport.com

    Recruiting

  • Erasmus Medisch Centrum

    Rotterdam, 3015 GD

    Boehringer Ingelheim, 08000204613, nederland@bitrialsupport.com

    Recruiting

Other trials in Netherlands

Norway3 sites, 3 recruiting

  • Haukeland Universitetssykehus

    Bergen, 5021

    Boehringer Ingelheim, 80058261, norge@bitrialsupport.com

    Recruiting

  • Oslo Universitetssykehus HF, Radiumhospitalet

    Oslo, N-0379

    Boehringer Ingelheim, 80058261, norge@bitrialsupport.com

    Recruiting

  • St. Olavs Hospital, Universitetssykehuset i Trondheim

    Trondheim, 7030

    Boehringer Ingelheim, 80058261, norge@bitrialsupport.com

    Recruiting

Other trials in Norway

Romania3 sites, 3 recruiting

  • Institutul Oncologic Prof. Dr. Alexandru Trestioreanu Bucuresti

    Bucharest, 022328

    Boehringer Ingelheim, 0800895209, romania@bitrialsupport.com

    Recruiting

  • Institute Of Oncology Prof. Dr. Ion Chiricuta Cluj-Napoca

    Cluj-Napoca, 400015

    Boehringer Ingelheim, 0800895209, romania@bitrialsupport.com

    Recruiting

  • Centrul De Oncologie SF Nectarie S.R.L.

    Craiova, 200542

    Boehringer Ingelheim, 0800895209, romania@bitrialsupport.com

    Not yet recruiting

Other trials in Romania

Sweden3 sites, 3 recruiting

  • Gävle sjukhus

    Gävle, 801 87

    Boehringer Ingelheim, 0200880001, sverige@bitrialsupport.com

    Recruiting

  • Sahlgrenska Universitetssjukhuset, Östra

    Gothenburg, 413 46

    Boehringer Ingelheim, 0200880001, sverige@bitrialsupport.com

    Recruiting

  • Karolinska Universitetssjukhuset Solna

    Stockholm, 171 76

    Boehringer Ingelheim, 0200880001, sverige@bitrialsupport.com

    Recruiting

Other trials in Sweden

Canada2 sites, 2 recruiting

  • Verspeeten Family Cancer Centre (LHSC)

    London, Ontario, N6A 5W9

    Boehringer Ingelheim, 18336022346, canada@bitrialsupport.com

    Not yet recruiting

  • Sault Area Hospital

    Sault Ste. Marie, Ontario, P6B 0A8

    Boehringer Ingelheim, 18336022346, canada@bitrialsupport.com

    Not yet recruiting

Other trials in Canada

Czechia2 sites, 2 recruiting

  • University Hospital Olomouc

    Olomouc, 77900

    Boehringer Ingelheim, 800142046, cesko@bitrialsupport.com

    Not yet recruiting

  • University Thomayer´s Hospital

    Prague, 140 59

    Boehringer Ingelheim, 800142046, cesko@bitrialsupport.com

    Not yet recruiting

Other trials in Czechia

Estonia2 sites, 2 recruiting

  • North Estonia Medical Centre Foundation, Tallinn

    Tallinn, 13419

    Boehringer Ingelheim, 8000044842, eesti@bitrialsupport.com

    Not yet recruiting

  • Tartu University Hospital

    Tartu, 50406

    Boehringer Ingelheim, 8000044842, eesti@bitrialsupport.com

    Not yet recruiting

Other trials in Estonia

Hong Kong2 sites, 2 recruiting

  • Queen Mary Hospital

    Hong Kong

    Boehringer Ingelheim, 800965365, hongkong@bitrialsupport.com

    Recruiting

  • Prince of Wales Hospital-Hong Kong-20715

    Shatin, 999077

    Boehringer Ingelheim, 800965365, hongkong@bitrialsupport.com

    Recruiting

Other trials in Hong Kong

Latvia2 sites, 2 recruiting

  • Pauls Stradins Clinical University Hospital

    Riga, 1002

    Boehringer Ingelheim, 80200224, latvia@bitrialsupport.com

    Not yet recruiting

  • Rigas Austrumu kliniska universitates slimnica SIA

    Riga, 1079

    Boehringer Ingelheim, 80200224, latvia@bitrialsupport.com

    Not yet recruiting

Other trials in Latvia

New Zealand2 sites, 2 recruiting

  • Auckland City Hospital

    Auckland, 1023

    Boehringer Ingelheim, 0800440725, newzealand@bitrialsupport.com

    Recruiting

  • Waikato Hospital

    Hamilton, 3204

    Boehringer Ingelheim, 0800440725, newzealand@bitrialsupport.com

    Recruiting

Other trials in New Zealand

Singapore2 sites, 2 recruiting

  • National Cancer Centre Singapore

    Singapore, 168583

    Boehringer Ingelheim, 8001207344, singapore@bitrialsupport.com

    Recruiting

  • Tan Tock Seng Hospital

    Singapore, 308433

    Boehringer Ingelheim, 8001207344, singapore@bitrialsupport.com

    Recruiting

Other trials in Singapore

Switzerland2 sites, 2 recruiting

  • Kantonsspital Baden AG

    Baden, 5404

    Boehringer Ingelheim, 0800005900, suisse@bitrialsupport.com

    Not yet recruiting

  • Centre Hospitalier Universitaire Vaudois

    Lausanne, 1011

    Boehringer Ingelheim, 0800005900, suisse@bitrialsupport.com

    Not yet recruiting

Other trials in Switzerland

Georgia1 site, 1 recruiting

  • ARENSIA Exploratory Medicine LLC

    Tbilisi, 0112

    Boehringer Ingelheim, 800008086, sakartvelo@bitrialsupport.com

    Recruiting

Other trials in Georgia

Ireland1 site, 1 recruiting

  • Cork University Hospital

    Cork, T12 DFK4

    Boehringer Ingelheim, 08000514022, unitedkingdom@bitrialsupport.com

    Not yet recruiting

Other trials in Ireland

Moldova1 site, 1 recruiting

  • ARENSIA Exploratory Medicine

    Chisinau, MD-2025

    Boehringer Ingelheim, 80060024, moldova@bitrialsupport.com

    Recruiting

Other trials in Moldova

About this study

Official title: DAREON ® -Lung-1: A Phase III Multi-center, Open-label, Randomised Trial of Intravenous Obrixtamig in Combination With Atezolizumab, Carboplatin, and Etoposide vs. Atezolizumab, Carboplatin, and Etoposide as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer

This study is open to adults with advanced small cell lung cancer (SCLC). The purpose of this study is to find out if a study medicine called obrixtamig plus standard treatment (atezolizumab, carboplatin, and etoposide) improves survival when compared to standard treatment alone. Obrixtamig is an antibody-like molecule that may help the immune system fight cancer. Another purpose of the study is to test a medical device being developed to measure levels of the tumour marker DLL3.

Participants are put into 2 groups randomly, which means by chance. One group receives obrixtamig and standard treatment. The other group receives standard treatment without obrixtamig. All treatments are given as infusions into a vein.

Participants are in the study for up to 3 years. During this time, they visit the study site regularly. Participants in the group receiving obrixtamig stay overnight at the study site following the first 2 obrixtamig treatments. At the visits, doctors check the size of the tumour(s). The results are compared between the 2 groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.

Being tested
obrixtamig, atezolizumab, carboplatin, etoposide
Medical subject headings
Small Cell Lung Carcinoma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07472517
Study groupRoleWhat they receive
obrixtamig + atezolizumab, carboplatin, and etoposide treatment armExperimentalNot described
Receives: Drug: obrixtamig; Drug: atezolizumab; Drug: carboplatin; Drug: etoposide
atezolizumab, carboplatin, and etoposide control armExperimentalNot described
Receives: Drug: atezolizumab; Drug: carboplatin; Drug: etoposide

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Overall survival (OS)

    OS, defined as the time from randomisation until death from any cause

    Measured: Up to 36 months

Secondary outcomes (10)

  1. Progression free survival (PFS)

    PFS, defined as the time from randomisation until the earliest date of tumour progression according to the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 based on investigator assessments or death from any cause

    Measured: Up to 36 months

  2. Change From Baseline in Selected Disease Symptoms Included in the European Organization for Research and Treatment of Lung Cancer Quality of Life Questionnaire (EORTC-QLQ-LC13)

    EORTC QLQ-LC13: European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire lung cancer-specific 13-item questionnaire module (QLQ-LC13) includes one multi-item scale (dyspnoea, based on three items) and ten single-item measures capturing symptoms such as coughing, haemoptysis, pain, and treatment-related toxicities including sore mouth, dysphagia, and peripheral neuropathy. All QLQ-LC13 items are scored on a 4-point Likert scale (1 = "not at all," 4 = "very much"). All QLQ-LC13 scores range from 0 to 100, with higher scores indicating greater symptom burden or more severe problems

    Measured: At baseline and up to 1 year

  3. Overall response (OR)

    OR, defined as a best overall response of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 (based on investigator assessments) from the date of randomisation until the earliest date of disease progression, death, last evaluable tumour assessment before start of subsequent anti-cancer therapy, lost to follow-up, or withdrawal of consent

    Measured: Up to 36 months

  4. Occurrence of treatment-emergent Cytokine Release Syndrome (CRS) during the on-treatment period

    Measured: Up to 36 months

  5. Occurrence of treatment-emergent Immune effector cell-associated neurotoxicity syndrome (ICANS) during the on-treatment period

    Measured: Up to 36 months

  6. Occurrence of treatment-emergent adverse events (AEs) leading to trial medication discontinuation during the on-treatment period

    Measured: Up to 36 months

  7. Occurrence of treatment-emergent AEs leading to trial medication dose delay during the on-treatment period

    Measured: Up to 36 months

  8. Occurrence of treatment-emergent AEs leading to trial medication dose reduction during the on-treatment period

    Measured: Up to 36 months

  9. Time to deterioration (TTD), defined as time from randomisation to deterioration maintained for 2 consecutive assessments or 1 assessment followed by death from any cause within 3 weeks

    Assessments are a composite of the following European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ EORTC) scores:

    • Dyspnea as measured by EORTC-QLQ-C30 and EORTC-QLQ-LC13
    • Chest pain as measured by EORTC-QLQ-LC13
    • Cough as measured by EORTC-QLQ-LC13 These questionnaires request scores on global health status, functioning, symptoms, as well as single items to assess dyspnoea, insomnia, appetite loss, constipation, diarrhoea and financial difficulties.

    All scores range from 0 to 100. For scores regarding functioning and global quality of life, higher scores represent better functioning and better quality of life. For scores regarding symptom scales higher scores indicate greater symptom burden.

    Measured: Up to 3 weeks

  10. Change From Baseline in Symptom Severity as Measured by scales of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-LC13

    EORTC QLQ-LC13: EORTC Quality of Life Questionnaire lung cancer-specific 13-item questionnaire module (QLQ-LC13) includes one multi-item scale (dyspnoea, based on three items) and ten single-item measures capturing symptoms such as coughing, haemoptysis, pain, and treatment-related toxicities including sore mouth, dysphagia, and peripheral neuropathy. All QLQ-LC13 items are scored on a 4-point Likert scale (1 = "not at all," 4 = "very much"). All QLQ-LC13 scores range from 0 to 100, with higher scores indicating greater symptom burden or more severe problems

    Measured: At baseline and up to 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Mar 2026
  2. Study start13 Apr 2026
  3. Primary completion9 Sep 2028 (estimated)
  4. Study completion30 Jul 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Open-label
Masking
None (open label)
Enrolment
670 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07472517
Sponsor's protocol ID
1438-0012
Other IDs
2025-520565-51-00, U1111-1317-4955, 2025
Status last verified
Oct 2026
First submitted
4 Mar 2026
Last updated
20 Oct 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing obrixtamig, atezolizumab and carboplatin in people with Small Cell Lung Cancer (SCLC) and Extensive-stage Small Cell Lung Cancer (ES-SCLC), run by Boehringer Ingelheim at 245 sites in 42 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 20 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 245 sites in China, United States, Spain, Germany, Japan and 37 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Boehringer Ingelheim (1-800-243-0127, clintriage.rdg@boehringer-ingelheim.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Overall survival (OS) (time frame: Up to 36 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07472517.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Oct 2026; AzTrials last refreshed its copy on 26 Oct 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in